Editas Medicine narrows Q3 2026 loss to $23.4M
Existing cash, cash equivalents and marketable securities are expected to fund operating expenses and capital expenditures into the second half of 2028.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Editas Medicine, Inc. (EDIT) reported third-quarter 2026 collaboration and other research and development revenue of $10.365 million, versus $7.543 million a year earlier, and net loss of $23.393 million, versus $25.117 million. The revenue increase primarily reflected recognition of a strategic partner’s clinical-development milestones. Cash, cash equivalents and marketable securities totaled $190.2 million as of September 30, 2026; Editas expects these resources to fund operating expenses and capital expenditures into the second half of 2028.
Editas received Australian HREC approval and completed the Clinical Trial Notification process to initiate the Phase 1/2 Strive study of EDIT-401 in patients with HeFH. It remains on track to begin patient dosing in 2026 and expects initial safety and tolerability data in the first quarter of 2027. Editas expects to complete Part 1 enrollment, with topline safety and efficacy results available in the second half of 2027. In ongoing non-human-primate studies, EDIT-401 showed ≥90% LDL-C reduction maintained over 10 months and ~90% mean Lp(a) and ApoB reductions maintained over three months. A second IND/CTA was accepted for Bristol Myers Squibb’s CD70 healthy-donor allogeneic CAR-T program, triggering a milestone payment to Editas.
2 points · 0 major0 major · 0 points
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointQuarterly collaboration revenue rose to $10.365 million from $7.543 million.
- Moderate pointQuarterly net loss narrowed to $23.393 million from $25.117 million.
Negative
- None.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Collaboration and other research and development revenue: $10.365 million
Net loss: $23.393 million
Net loss per share, basic and diluted: ($0.15) per share
+4 more
7 metrics
Collaboration and other research and development revenue
$10.365 million
Three months ended September 30, 2026; $7.543 million in the same period of 2025
Net loss
$23.393 million
Three months ended September 30, 2026; $25.117 million in the same period of 2025
Net loss per share, basic and diluted
($0.15) per share
Three months ended September 30, 2026; ($0.28) per share in the same period of 2025
Research and development expense
$21.170 million
Three months ended September 30, 2026; $19.775 million in the same period of 2025
General and administrative expense
$13.477 million
Three months ended September 30, 2026; $12.316 million in the same period of 2025
Cash, cash equivalents and marketable securities
$190.2 million
As of September 30, 2026
Expected cash runway
Into the second half of 2028
Expected funding period for operating expenses and capital expenditure requirements
Key Terms
Human Research Ethics Committee (HREC), Clinical Trial Notification (CTN), Heterozygous Familial Hypercholesterolemia (HeFH), IND/CTA, +2 more
6 terms
Human Research Ethics Committee (HREC) regulatory
"received Human Research Ethics Committee (HREC) approval"
A human research ethics committee (HREC) is an independent panel that reviews and approves studies involving people to make sure risks are minimized, consent is informed, and welfare is protected—like a safety inspector for medical research. For investors, HREC approval matters because it is often required before clinical work can start or continue; it affects development timelines, regulatory acceptance, and the credibility and legal risk of a company’s human-subject research.
Clinical Trial Notification (CTN) regulatory
"completed the Clinical Trial Notification (CTN) process"
A clinical trial notification (CTN) is a formal notice filed with regulators or ethics bodies before enrolling people in a human drug or device study; it summarizes the study plan, safety measures, informed consent process and who is legally responsible for the trial. For investors, a CTN is a key regulatory milestone that affects whether a trial can start, how quickly a product can move toward approval, and the project’s risk and timeline — like securing a permit before construction.
Heterozygous Familial Hypercholesterolemia (HeFH) medical
"patients with Heterozygous Familial Hypercholesterolemia (HeFH)"
IND/CTA regulatory
"a second IND/CTA was accepted for an alpha-beta T cell medicine"
An IND/CTA is a formal regulatory submission that asks health authorities for permission to test an experimental drug or treatment in humans — IND is the U.S. route, CTA is the equivalent in many other countries. Think of it as the safety permit a developer must obtain before starting human trials; investors watch these filings because approval clears a major regulatory hurdle, changes development timelines and risk, and can materially affect a program’s value and funding needs.
LDL-C medical
"LDL-C reduction of ≥90 percent with EDIT-401"
LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.
Lp(a) medical
"mean Lp(a) and ApoB reductions"
Lp(a), or lipoprotein(a), is a blood particle that carries cholesterol and a specific protein; think of it as a delivery truck that can drop off harmful cargo along artery walls. High Lp(a) levels are linked to increased risk of heart disease and stroke, so changes in testing, treatments, or clinical results for Lp(a) can affect healthcare costs, drug prospects, and investor expectations for companies working on cardiovascular diagnostics or therapies.
Earnings Snapshot
Collaboration and other research and development revenue: $10.365 million · Guidance included
Three months ended September 30, 2026
Collaboration and other research and development revenue
$10.365 million
Compared with $7.543 million in the same period of 2025
Net loss
$23.393 million
Compared with $25.117 million in the same period of 2025
Net loss per share, basic and diluted
($0.15) per share
Compared with ($0.28) per share in the same period of 2025
Guidance
Editas expects its existing cash, cash equivalents and marketable securities to fund operating expenses and capital expenditure requirements into the second half of 2028.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were EDIT's third-quarter 2026 R&D and G&A expenses?
For the three months ended September 30, 2026, R&D expense was $21.170 million, versus $19.775 million, and G&A expense was $13.477 million, versus $12.316 million, in the same period of 2025. The R&D increase primarily reflected higher sublicense and license fees and EDIT-401 development, partly offset by lower employee-related and external R&D costs. G&A expense rose primarily due to higher intellectual property and patent-related fees.
What is the update on Editas' Bristol Myers Squibb collaboration?
A second IND/CTA was accepted for BMS-986527, a CD70 healthy-donor allogeneic CAR-T therapy, triggering a milestone payment to Editas. Bristol Myers Squibb will advance the program in a Phase 1 study evaluating safety and tolerability in participants with clear cell renal cell carcinoma. Editas developed the Cas12a gene-editing technology used to engineer the CAR-T cells.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________________________________________
FORM 8-K
_________________________________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 9, 2026
_________________________________________________________________________________________
(Exact Name of Registrant as Specified in its Charter)
_________________________________________________________________________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
Registrant’s telephone number, including area code: (617 ) 401-9000
(Former Name or Former Address, if Changed Since Last Report)
__________________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On November 9, 2026, Editas Medicine, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended September 30, 2026 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press release issued by the Company on November 9, 2026* | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
*This exhibit shall be deemed to be furnished and not filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EDITAS MEDICINE, INC. | ||||||||
| Date: November 9, 2026 | By: | /s/ Amy Parison | ||||||
| Amy Parison | ||||||||
| Chief Financial Officer | ||||||||
Editas Medicine Announces Third Quarter 2026 Results and Business Updates
Company received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia
New preclinical data presented at AHA Scientific Sessions demonstrating ≥90 percent LDL-C reduction maintained over 10 months supports EDIT-401's potential best-in-class profile
Second IND/CTA accepted for CD70 HD Allo CAR T program as part of collaboration with Bristol Myers Squibb, triggering milestone payment to Editas
Cash runway into second half of 2028, through and beyond key clinical readouts from Strive study
CAMBRIDGE, Mass., November 9, 2026 – Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the third quarter 2026 and provided business updates.
“We are incredibly excited by the progress we made in the third quarter as we advanced EDIT-401, our potentially best-in-class in vivo gene editing medicine for hyperlipidemia, towards the clinic,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. “The recent regulatory and ethics approval to initiate the Strive study in Australia and new preclinical durability data presented at AHA represent important milestones for EDIT-401, and, more importantly, for patients living with hyperlipidemia. Backed by this momentum and our strong cash position, we look forward to executing on the Strive study and generating additional data in 2027.”
EDIT-401
•Editas received Human Research Ethics Committee (HREC) approval and completed the Clinical Trial Notification (CTN) process with Australia’s Therapeutic Goods Administration (TGA) to initiate the Phase 1/2 Strive study of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH) in Australia.
◦The Company remains on track to begin patient dosing this year and report initial safety and tolerability data in the first quarter of 2027.
◦The Company expects to complete enrollment in Part 1 of the Strive study, with topline safety and efficacy results from Part 1 available in the second half of 2027.
•Editas shared new EDIT-401 preclinical data in an oral presentation at the American Heart Association (AHA) Scientific Sessions 2026 in November demonstrating durable LDL-C lowering with EDIT-401 and further supporting its potential as a transformative, one-time treatment for people living with hyperlipidemia. Key data presented included:
◦LDL-C reduction of ≥90 percent with EDIT-401 was maintained over 10 months in an ongoing study in non-human primates (NHPs).
◦EDIT-401 achieved ~90 percent mean Lp(a) and ApoB reductions, which was maintained over three months in an ongoing study in NHPs.
◦Consistent safety profile with targeted delivery to the liver, transient elevations in LFTs, no histopathologic findings, and no evidence of genotoxicity in relevant primary human cells.
Corporate & Business Development Updates
•In October, Editas presented two posters at the 33rd Annual European Society of Gene and Cell Therapy (ESGCT) Congress with preclinical data demonstrating robust in vivo delivery of mRNA to targeted T-cells with the Company’s novel, scalable platform for targeted lipid nanoparticle (tLNP) extrahepatic delivery, as well as data highlighting how platform-driven LNP process development can accelerate development timelines, mitigate scale-up risk, and effectively bridge discovery-stage innovation with the clinic, enabling the next generation of in vivo genetic medicines.
•In September, Editas announced the appointment of Dan Ory, M.D., as Chief Medical Officer. With more than 25 years of experience spanning biotechnology leadership, cardiovascular medicine, and the development of genetic medicines, Dr. Ory will oversee the Company's clinical development strategy and operations as Editas advances EDIT-401 into the clinic, while supporting the progression of the company's broader pipeline.
•As part of the Company’s collaboration agreement with Bristol Myers Squibb, a second IND/CTA was accepted for an alpha-beta T cell medicine, triggering a milestone payment to Editas. BMS will advance this second collaboration product, BMS-986527, a CD70 healthy-donor allogeneic CAR-T therapy, in a Phase 1 clinical study evaluating its safety and tolerability in participants with clear cell renal cell carcinoma, the most common form of kidney cancer. Editas developed the Cas12a gene editing technology used to engineer the CAR-T cells.
Upcoming Events
Editas Medicine plans to participate in the following investor event:
•9th Annual Evercore Healthcare Conference
Format: Fireside Chat
Date: November 30, 2026
Time: 3:25 p.m. ET
Location: Coral Gables, FL
To access a live webcast of the Fireside Chat, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the event.
Third Quarter 2026 Financial Results
•Cash, cash equivalents, and marketable securities as of September 30, 2026, were $190.2 million compared to $146.6 million as of December 31, 2025. The Company expects that its existing cash, cash equivalents, and marketable securities will enable the Company to fund its operating expenses and capital expenditure requirements into the second half of 2028.
•For the three months ended September 30, 2026, net loss attributable to common stockholders was $23.4 million, or $0.15 per share, compared to net loss of $25.1 million, or $0.28 per share, for the same period in 2025.
•Collaboration and other research and development revenues increased to $10.4 million for the three months ended September 30, 2026, compared to $7.5 million for the same period in 2025. The increase was primarily attributable to revenue recognized in connection with clinical development milestones achieved by a strategic partner.
•Research and development expenses increased by $1.4 million to $21.2 million for the three months ended September 30, 2026, compared to $19.8 million for the same period in 2025. The increase was primarily related to higher sublicense and license fees as well as increased costs associated with the continued development of EDIT-401. These increases were partially offset by lower employee-related costs and external research and development costs.
•General and administrative expenses increased by $1.2 million to $13.5 million for the three months ended September 30, 2026, compared to $12.3 million for the same period in 2025. The increase was primarily attributable to higher intellectual property and patent-related fees due to increased legal activity related to intellectual property defense.
About EDIT-401
EDIT-401 is an experimental, potentially best-in-class in vivo gene editing medicine, based on Editas’ differentiated upregulation approach. EDIT-401 is designed to treat hyperlipidemia by directly editing the LDLR gene to increase LDLR protein expression and reduce LDL-C levels. This targeted approach has demonstrated a favorable preclinical profile in both efficacy data and tolerability and supports the potential of EDIT-401 to deliver meaningful clinical outcomes for patients underserved by current lipid-lowering therapies.
About Heterozygous Familial Hypercholesterolemia (HeFH)
Heterozygous Familial Hypercholesterolemia (HeFH) is an inherited genetic disorder that leads to significantly elevated LDL‑cholesterol levels from an early age. Individuals with HeFH are at high risk of heart disease, heart attack, or stroke if the condition is not identified and treated early. An estimated 1.2 million people in the United States are living with HeFH, though many remain undiagnosed. Elevated LDL-C, also known as hyperlipidemia, is a highly prevalent disease affecting over 70 million patients in the United States alone. Substantial unmet need exists across multiple at-risk segments of patients with hyperlipidemia, including the HeFH population.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the initiation, timing, progress and results of the Company’s preclinical studies and planned clinical trials, including the Company’s expectation to begin patient dosing in 2026 and complete enrollment in Part 1 of the Strive study, with topline safety and efficacy results from Part 1 available in the second half of 2027; the timing for the Company’s receipt and presentation of data from its preclinical and planned clinical studies, including reporting initial safety and tolerability data in the first quarter of 2027; the potential of, and expectations for, EDIT-401; the timing or likelihood of regulatory submissions and approvals; and the Company’s expectations regarding its cash runway. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation, timing, progress, and
results of preclinical studies and clinical trials; uncertainty regarding availability and timing of results from preclinical studies and clinical trials; uncertainties relating to planned regulatory submissions to initiate clinical trials, including that results of preclinical studies will warrant such submissions or that regulatory agencies may require additional preclinical studies, that regulatory submissions shall occur on the expected timelines and that regulatory authorities will provide clearance for trials to be initiated on the expected timelines or at all; and uncertainties as to whether the Company’s cash resources are sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements for the period anticipated. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
EDITAS MEDICINE, INC.
Condensed Consolidated Statements of Operations
(amounts in thousands, except share and per share data)
(Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Collaboration and other research and development revenues | $ | 10,365 | $ | 7,543 | $ | 25,086 | $ | 15,779 | |||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Research and development | 21,170 | 19,775 | 58,950 | 62,549 | |||||||||||||||||||
| General and administrative | 13,477 | 12,316 | 35,314 | 38,550 | |||||||||||||||||||
| Restructuring and impairment charges | — | — | (1,339) | 66,935 | |||||||||||||||||||
| Total operating expenses | 34,647 | 32,091 | 92,925 | 168,034 | |||||||||||||||||||
| Operating loss | (24,282) | (24,548) | (67,839) | (152,255) | |||||||||||||||||||
| Other income (expense), net: | |||||||||||||||||||||||
| Interest expense related to sale of future revenues | (1,082) | (2,399) | (3,215) | (6,635) | |||||||||||||||||||
| Interest income, net | 1,972 | 1,831 | 4,546 | 6,634 | |||||||||||||||||||
| Other expense, net | (1) | (1) | (97) | (2,184) | |||||||||||||||||||
| Total other income (expense), net | 889 | (569) | 1,234 | (2,185) | |||||||||||||||||||
| Net loss | $ | (23,393) | $ | (25,117) | $ | (66,605) | $ | (154,440) | |||||||||||||||
| Net loss per share, basic and diluted | $ | (0.15) | $ | (0.28) | $ | (0.54) | $ | (1.80) | |||||||||||||||
| Weighted-average common shares outstanding, basic and diluted | 153,604,267 | 90,090,397 | 123,796,862 | 85,878,325 | |||||||||||||||||||
EDITAS MEDICINE, INC.
Selected Condensed Consolidated Balance Sheet Items
(amounts in thousands)
(Unaudited)
| September 30, | December 31, | ||||||||||
| 2026 | 2025 | ||||||||||
| Cash and cash equivalents | $ | 93,169 | $ | 146,645 | |||||||
| Marketable securities | 97,029 | — | |||||||||
| Working capital | 130,391 | 117,649 | |||||||||
| Total assets | 219,412 | 186,534 | |||||||||
| Deferred revenue, current | 32,315 | — | |||||||||
| Deferred revenue, net of current portion | 4,000 | 44,509 | |||||||||
| Total stockholders’ equity | 84,520 | 27,288 | |||||||||
###
Investor and Media Contacts:
ir@editasmed.com
media@editasmed.com